• RenovoRx outlined a commercial ramp for its FDA-cleared RenovoCath drug-delivery catheter, citing 16 active US cancer centers and a pipeline of 32 additional centers in evaluation or onboarding as of May 6, 2026.
• Projected 2026 revenue of $3-4 million; targeted 36 active commercial cancer centers by year-end.
• Reported $1.1 million in RenovoCath revenue in 2025; recorded $563,000 in Q1 2026, more than half of the prior-year total.
• Highlighted a potential peak annual US revenue opportunity of about $400 million for RenovoCath as a standalone device; cited pricing benchmarks of $6,000-$8,500 per unit and 5-6 procedures per patient.
• Updated its Phase III TIGeR-PaC study of intra-arterial gemcitabine delivered via RenovoCath in locally advanced pancreatic cancer, with 106 patients randomized and 74 events as of May 14, 2026; enrollment completion anticipated in June 2026 and final analysis expected in mid-late 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on May 23, 2026, and is solely responsible for the information contained therein.